Author Page for Myung-Ju Ahn

A Phase 1b Study of Osimertinib Plus Savolitinib in Patients with EGFR Mutation-Positive, MET-Amplified, Non-Small Cell Lung Cancer after Progression on EGFR-Tyrosine Kinase Inhibitors

Number of pages: 222 Posted: 03 Oct 2019

Lecia V. Sequist, Ji-Youn Han, Myung-Ju Ahn, Byoung Chul Cho, Helena Yu, Sang-We Kim, James Chih-Hsin Yang, Jong Seok Lee, Wu-Chou Su, Dariusz Kowalski, Sergey Orlov, Mireille Cantarini, Remy B. Verheijen, Anders Mellemgaard, Paul Frewer, Xiaoling Ou and Geoffrey Oxnard

Harvard University - Department of Medicine, National Cancer Center, Korea, Sungkyunkwan University - Division of Hematology-Oncology, Yonsei University - Yonsei Cancer Center, Memorial Sloan Kettering Cancer Center, University of Ulsan - Department of Oncology, National Taiwan University - Department of Oncology, Seoul National University - Department of Internal Medicine, National Cheng Kung University - Department of Internal Medicine, Maria Skłodowska-Curie Institute of Oncology, BioEq, LLC, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - United Kingdom and Harvard University - Department of Thoracic Oncology

Downloads 129 (561,789)

Citation 1

Abstract:

2.

Randomized Phase II Study of Axitinib Versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma

Number of pages: 30 Posted: 25 Jan 2021

Eun Joo Kang, Myung-Ju Ahn, Chan-Young Ock, Keun-Wook Lee, Jung Hye Kwon, Yaewon Yang, Yoon Hee Choi, Min Kyoung Kim, Jun Ho Ji, Tak Yun, Byung Ho Nam, Sung-Bae Kim and Bhumsuk Keam

Korea University - Department of Internal Medicine, Sungkyunkwan University - Division of Hematology-Oncology, Seoul National University - Department of Internal Medicine, Seoul National University - Department of Internal Medicine, Chungnam National University - Department of Internal Medicine, Chungbuk National University - Chungbuk National University Hospital, Cancer Center, Korea - Dongnam Institute of Radiological and Medical Sciences, Yeungnam University - Department of Internal Medicine, Sungkyunkwan University - Samsung Changwon Hospital, Chinese Academy of Medical Sciences - National Cancer Center, Institute of Advanced Clinical and Biomedical Research, University of Ulsan - Department of Oncology and Seoul National University - Department of Internal Medicine

Downloads 114 (626,371)

Abstract:

3.

Comprehensive Genomic Analysis of Non-Small Cell Lung Cancer for Predicting Treatment Response to Immunotherapy

Number of pages: 40 Posted: 17 Jun 2019

Joon Ho Shim, Hong Sook Kim, Hongui Cha, Yoon-La Choi, Hyun Ae Jung, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Soyeon Kim, Tae Min Kim, Keunchil Park, Woong-Yang Park and Se-Hoon Lee

Sungkyunkwan University - School of Medicine, Seoul National University Cancer Research Institute, Sungkyunkwan University - School of Medicine, Sungkyunkwan University - School of Medicine, Sungkyunkwan University - Samsung Medical Center, Sungkyunkwan University - Division of Hematology-Oncology, Sungkyunkwan University - Division of Hematology-Oncology, Sungkyunkwan University - Division of Hematology-Oncology, Seoul National University Cancer Research Institute, Seoul National University - Seoul National University Boramae Hospital, Sungkyunkwan University - Division of Hematology-Oncology, Sungkyunkwan University - School of Medicine and Sungkyunkwan University - Division of Hematology-Oncology

Downloads 67 (899,324)

Myung-Ju Ahn

Sungkyunkwan University - Division of Hematology-Oncology

3

310

1

Scholarly Papers (3)

A Phase 1b Study of Osimertinib Plus Savolitinib in Patients with EGFR Mutation-Positive, MET-Amplified, Non-Small Cell Lung Cancer after Progression on EGFR-Tyrosine Kinase Inhibitors

Abstract:

Randomized Phase II Study of Axitinib Versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma

Abstract:

Comprehensive Genomic Analysis of Non-Small Cell Lung Cancer for Predicting Treatment Response to Immunotherapy

Abstract: